Skip to main content
Premium Trial:

Request an Annual Quote

Gibson Leaves Affy, Collins Gets a Prize, Haas Takes the Helm at Plexigen, and More

NEW YORK (GenomeWeb News) - James Gibson has resigned his position as Affymetrix’s VP and principal accounting officer. Gibson is leaving his post at Affy in order to pursue a senior financial management job at another company, Affy said in a filing with the US Securities and Exchange Commission.

Exosome Diagnostics has added three new faces to its scientific advisory board, including Dennis Brown, Xandra Breakefield, and Richard Edelson.
Brown is director of Massachusetts’s General Hospitals program in membrane biology and a professor at Harvard Medical School. Breakefield is a geneticist at Mass General and a professor of neurology at Harvard Medical School. Edelson is director of the Yale Cancer Center and is a professor at Yale University School of Medicine.

Former National Human Genome Research Institute Director Francis Collins has been named winner of the Inamori Ethics Prize from the Inamori International Center for Ethics and Excellence at Case Western Reserve University. The award includes a $25,000 cash prize that is intended to support the awardee’s further research.

Molecular biologist Joseph DeRisi has been awarded one of this year’s $250,000 Heinz Awards, named for US Senator John Heinz, for his diagnostics-on-a-chip research. The University of California, San Francisco, scientist invented the ViroChip, a microarray holding 22,000 DNA sequences from over 1,300 viral families.

Metabolon has appointed Edward Erickson to its board of directors. Erickson serves as a board member, advisor, and consultant to other life science companies and venture capital firms, and he has overseen development and FDA clearance of diagnostic products, Metabolon said.

Bill Haas has taken the job of president and CEO at Plexigen. Haas formerly was executive VP of esoteric business at Laboratory Corporation of America, where he was employed for 18 years.

Georgia’s Centers of Innovation has appointed Stacy Williams to be director of the life sciences program, which is aimed at enhancing growth in the state’s life sciences and biotechnology industries and is located at the Medical College of Georgia in Augusta.

Power3 Medical Products has named Helen Park to be the company's interim CEO, after Steven Rash resigned from that post and his position as chairman last week. Park is a co-founder of Advanced BioChem, where she was CEO and chairman of the board of directors, and she is founder of Bronco Technology.
The company also named Ira Goldknopf to be president and interim board chairman, and he will retain his role as chief scientific officer.

BioMerieux Corporate VP of Business Development and Theranostics Richard Ding has been named CEO of the firm’s new subsidiary, bioTheranostics. He also will continue to serve on BioMerieux’s management committee and will continue to lead BioMerieux’s business development and theranostics activities.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.